BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21585373)

  • 1. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
    J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
    Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
    Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
    Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
    Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
    J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.
    Zhang W; Wang G; Falconer JR; Baguley BC; Shaw JP; Liu J; Xu H; See E; Sun J; Aa J; Wu Z
    Pharm Res; 2015 Apr; 32(4):1451-61. PubMed ID: 25355460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
    Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
    Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
    Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel liposomal gefitinib (L-GEF) formulations.
    Zhou X; Yung B; Huang Y; Li H; Hu X; Xiang G; Lee RJ
    Anticancer Res; 2012 Jul; 32(7):2919-23. PubMed ID: 22753756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C; Cui J; Wang C; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
    Int J Pharm; 2008 Oct; 362(1-2):60-6. PubMed ID: 18598745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
    Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation.
    Zhang W; Wang G; See E; Shaw JP; Baguley BC; Liu J; Amirapu S; Wu Z
    J Control Release; 2015 Apr; 203():161-9. PubMed ID: 25701612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
    Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
    Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfosalicylate mediates improved vinorelbine loading into LUVs and antineoplastic effects.
    Li C; Cui J; Wang C; Cao J; Zhang L; Li Y; Liang M; Xiu X; Li Y; Wei N; Deng C
    J Liposome Res; 2012 Mar; 22(1):42-54. PubMed ID: 21696260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.
    Yoshino K; Nakamura K; Terajima Y; Kurita A; Matsuzaki T; Yamashita K; Isozaki M; Kasukawa H
    Biochim Biophys Acta; 2012 Nov; 1818(11):2901-7. PubMed ID: 22828450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.